利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

6 条记录 (耗时 0.023 秒)

    Anti-human IL-21 monoclonal antibodies
    1.
    发明公开
    Anti-human IL-21 monoclonal antibodies 有权
    Monoklonale抗人IL-21-Antikörper

    公开(公告)号：EP2426146A2

    公开(公告)日：2012-03-07

    申请号：EP11185989.8

    申请日：2008-12-08

    申请人： ZymoGenetics, Inc.

    发明人： Jaspers, Stephen R. ,  Rixon, Mark W. ,  Dillon, Stacey R. ,  Ramsdell, Frederick J. ,  Krejsa, Cecile M. ,  Yi, Eugene C.

    IPC分类号： C07K16/24

    CPC分类号： C07K16/244 ,  A61K2039/505 ,  C07K2317/34 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/73 ,  C07K2317/76 ,  Y10S530/809

    摘要： There is provided an anti-human IL-21 monoclonal antibody comprising: (a) a heavy chain region comprising: (i) a heavy chain variable region CDR1 comprising SEQ ID NO: 63; (ii) a heavy chain variable region CDR2 comprising SEQ ID NO: 65; and (iii) a heavy chain variable region CDR3 comprising SEQ ID NO: 67; and (b) a light chain region comprising: (i) a light chain variable region CDR1 comprising SEQ ID NO: 71; (ii) a light chain variable region CDR2 comprising SEQ ID NO: 73; and (iii) a light chain variable region CDR3 comprising SEQ ID NO: 75. There is also provided a hybridoma designated 366.328.10, wherein the hybridoma is deposited with the American Type Culture Collection having the ATCC Patent Deposit Designation PTA-8789.

    摘要翻译： 提供抗人IL-21单克隆抗体，其包含：（a）重链区，其包含：（i）包含SEQ ID NO：63的重链可变区CDR1; （ii）包含SEQ ID NO：65的重链可变区CDR2; 和（iii）包含SEQ ID NO：67的重链可变区CDR3; 和（b）轻链区，其包含：（i）包含SEQ ID NO：71的轻链可变区CDR1; （ii）包含SEQ ID NO：73的轻链可变区CDR2; 还提供了包含SEQ ID NO：75的轻链可变区CDR3。还提供了称为366.328.10的杂交瘤，其中杂交瘤保藏在具有ATCC专利保藏号PTA-8789的美国典型培养物保藏中心。

    Compositions and methods for inhibiting PDGFRBETA and VEGF-A
    5.
    发明公开
    Compositions and methods for inhibiting PDGFRBETA and VEGF-A 审中-公开
    Zusammensetzungen und Verfahren zur Hemmung von PDGFR-β和VEGF-A

    公开(公告)号：EP2604280A3

    公开(公告)日：2013-10-16

    申请号：EP13159556.3

    申请日：2009-03-27

    申请人： ZymoGenetics, Inc.

    发明人： Sivakumar, Pallavur V. ,  Gilbertson, Debra G. ,  Snavely, Marshall D. ,  Mabry, George R. ,  Yi, Eugene C. ,  Yao, Yue ,  Presnell, Scott R.

    IPC分类号： A61K39/395 ,  A61P35/00 ,  C07K16/22 ,  C07K16/28

    CPC分类号： C07K16/00 ,  A61K2039/505 ,  C07K16/22 ,  C07K16/2863 ,  C07K2317/21 ,  C07K2317/31 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/55 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2317/77 ,  C07K2317/90 ,  C07K2317/92

    摘要： There is provided an isolated antibody that binds to the extracellular domain of PDGFRβ and neutralizes PDGFRβ activity, said antibody comprising a V L domain comprising CDRs LCDR1, LCDR2, and LCDR3 and a V H domain comprising CDRs HCDR1, HCDR2, and HCDR3, wherein:
    LCDR1 has the amino acid sequence shown in SEQ ID NO: 433, optionally the amino acid sequence shown in SEQ ID NO: 443;
    LCDR2 has the amino acid sequence shown in SEQ ID NO: 434;
    LCDR3 has the amino acid sequence shown in SEQ ID NO: 435, optionally the amino acid sequence shown in SEQ ID NO: 444;
    HCDR1 has the amino acid sequence shown in SEQ ID NO: 436, optionally the amino acid sequence shown in SEQ ID NO: 445;
    HCDR2 has the amino acid sequence shown in SEQ ID NO: 437;
    HCDR3 has an amino acid sequence selected from the group consisting of SEQ ID NOs: 438-442

    摘要翻译： 提供了结合PDGFR2的细胞外结构域并中和PDGFR2活性的分离的抗体，所述抗体包含包含CDR1 LCDR1，LCDR2和LCDR3的VL结构域和包含CDR HCDR1，HCDR2和HCDR3的VH结构域，其中：LCDR1具有 SEQ ID NO：433所示的氨基酸序列，任选地SEQ ID NO：443所示的氨基酸序列; LCDR2具有SEQ ID NO：434所示的氨基酸序列; LCDR3具有SEQ ID NO：435所示的氨基酸序列，任选地SEQ ID NO：444所示的氨基酸序列; HCDR1具有SEQ ID NO：436所示的氨基酸序列，任选地是SEQ ID NO：445所示的氨基酸序列; HCDR2具有SEQ ID NO：437所示的氨基酸序列; HCDR3具有选自SEQ ID NO：438-442的氨基酸序列

    Compositions and methods for inhibiting PDGFRBETA and VEGF-A
    6.
    发明公开
    Compositions and methods for inhibiting PDGFRBETA and VEGF-A 审中-公开
    用于抑制PDGFRBETA和VEGF-A的组合物和方法

    公开(公告)号：EP2604280A2

    公开(公告)日：2013-06-19

    申请号：EP13159556.3

    申请日：2009-03-27

    申请人： ZymoGenetics, Inc.

    发明人： Sivakumar, Pallavur V. ,  Gilbertson, Debra G. ,  Snavely, Marshall D. ,  Mabry, George R. ,  Yi, Eugene C. ,  Yao, Yue ,  Presnell, Scott R.

    IPC分类号： A61K39/395 ,  A61P35/00 ,  C07K16/22 ,  C07K16/28

    CPC分类号： C07K16/00 ,  A61K2039/505 ,  C07K16/22 ,  C07K16/2863 ,  C07K2317/21 ,  C07K2317/31 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/55 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2317/77 ,  C07K2317/90 ,  C07K2317/92

    摘要： There is provided an isolated antibody that binds to the extracellular domain of PDGFRβ and neutralizes PDGFRβ activity, said antibody comprising a V L domain comprising CDRs LCDR1, LCDR2, and LCDR3 and a V H domain comprising CDRs HCDR1, HCDR2, and HCDR3, wherein:
    LCDR1 has the amino acid sequence shown in SEQ ID NO: 433, optionally the amino acid sequence shown in SEQ ID NO: 443;
    LCDR2 has the amino acid sequence shown in SEQ ID NO: 434;
    LCDR3 has the amino acid sequence shown in SEQ ID NO: 435, optionally the amino acid sequence shown in SEQ ID NO: 444;
    HCDR1 has the amino acid sequence shown in SEQ ID NO: 436, optionally the amino acid sequence shown in SEQ ID NO: 445;
    HCDR2 has the amino acid sequence shown in SEQ ID NO: 437;
    HCDR3 has an amino acid sequence selected from the group consisting of SEQ ID NOs: 438-442

    摘要翻译： 提供了与PDGFRβ的胞外结构域结合并中和PDGFRβ活性的分离的抗体，所述抗体包含含有CDR LCDR1，LCDR2和LCDR3的VL结构域和包含CDR HCDR1，HCDR2和HCDR3的VH结构域，其中：LCDR1具有 SEQ ID NO：433所示的氨基酸序列，任选的SEQ ID NO：443所示的氨基酸序列; LCDR2具有SEQ ID NO：434所示的氨基酸序列; LCDR3具有SEQ ID NO：435所示的氨基酸序列，任选地SEQ ID NO：444所示的氨基酸序列; HCDR1具有SEQ ID NO：436中所示的氨基酸序列，任选地SEQ ID NO：445中所示的氨基酸序列; HCDR2具有SEQ ID NO：437所示的氨基酸序列; HCDR3具有选自SEQ ID NO：438-442的氨基酸序列